Skip to content

Tina Nguyen

University of Calgary, AB, Canada.

2 papers in the library · 2 citations · publishing 2025-2026

Papers

"Facing Death. . . Now, That's a Serious Thing to Confront" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.

Integrative cancer therapies January 1, 2025 Haley D M Schuman, Sofia Barkova, Raèf Mina et al. 2 citations

People with cancer often experience deep existential distress that standard psychosocial care does not adequately address. In this qualitative study, 15 participants with various cancer types and stages shared their views on psychedelic-assisted therapy (PAT) as a possible way to relieve psychosocial suffering, especially existential and emotional distress. Four main themes emerged: cautious optimism and differing attitudes toward specific psychedelics; the influence of relationships, stigma, and cultural framing; structural barriers like cost, legality, and unequal access; and the cancer context itself, where unmet needs for existential and spiritual support are common, particularly after active treatment or at advanced stages. Participants saw PAT as a potential adjunct to conventional care but raised concerns about safety, access, and stigma, highlighting the need for equitable, patient-informed implementation.

Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".

Global advances in integrative medicine and health January 1, 2026 Haley D M Schuman, Raèf Mina, Sofia Barkova et al.

Healthcare providers in Canada hold cautious to supportive views on psychedelic-assisted therapy, with ketamine pragmatically accepted for its rapid effects but raising concerns about commercialization, psilocybin seen as promising for end-of-life existential distress yet viewed with mixed feelings, and MDMA considered useful for trauma but constrained by neurotoxicity worries and regulatory barriers. An ethical tension emerged between access to medical assistance in dying and restrictions on psychedelic-assisted therapy in end-of-life care, highlighting policy inconsistencies. Providers emphasized the need for substance-specific guidelines, interdisciplinary education, and evidence-informed regulatory reform.